Receptor News and Research

RSS

Study describes mechanism that limits immunosupressive activity of tumor-associated macrophages

Tumor cells are able to avoid the attack of the immune system through several mechanisms. For instance, these can secrete factors that turn macrophages -cells in the immune system- into dual action agents that contribute to the tumor progress and will protect it from immune body defenses: these become, thus, the tumor-associated macrophages (TAMs).

13 Feb 2021

Scientists demonstrate how glue points and sequence alignment information can flag residue SARS-CoV-2 variants

Researchers in the U.S. have demonstrated how dominant energetic landscape mappings or glue points, along with sequence alignment information can potentially identify key residue mutations and spike protein deletions tied with emerging variants.

12 Feb 2021

Study shows that SRC-3 also regulates human immune T regulatory cells

A study led by researchers at Baylor College of Medicine reveals a novel role of the steroid receptor coactivator 3 (SRC-3/NCOA3), a protein crucial for steroid hormone function and a prognostic marker for aggressive human breast and other cancers.

12 Feb 2021

Researchers identify a pathway used by filoviruses to enter cells

It was once thought that Ebola and related filoviruses were more or less contained to Central Africa.

11 Feb 2021

Brain pericytes serve as a potential hub for SARS-CoV-2 infection

A team of scientists from the United States has recently conducted a study using pericyte-like cell-containing brain cortical organoids as an experimental model to investigate the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the central nervous system.

11 Feb 2021

Higher proportion of male children develop COVID-19-related Multisystem Inflammatory Syndrome, finds study

Previous studies about COVID-19 have shown that the illness is often more severe in men than women. However, there is limited data available for the pediatric population. Though children and adolescents are at a lower risk of developing severe illness, some may experience severe symptoms. In some cases, children develop complications, including the multisystem inflammatory syndrome in children (MIS-C). Researchers report that a higher percentage of male children developed MIS-C and died.

11 Feb 2021

New gut microbiome-based approach may have translational potential for cancer immunotherapy

Scientists from Nanjing University and the University of Macau have devised a new approach to extend the survival of transplanted probiotics in vivo, enhancing the efficacy of cancer chemo-/immunotherapies in mice.

11 Feb 2021

New strategy to optimize the efficacy of neuropeptides for therapeutic applications

Dimerization (Note: combination of two identical or different molecules) of the human neuropeptides oxytocin and vasopressin can produce new types of bioactive molecules.

10 Feb 2021

Study could help develop drugs for pregnancy maintenance, treat autoimmune diseases

A team of scientists from Immanuel Kant Baltic Federal University with their colleagues from the Institute of Ecology and Genetics of Microorganisms of the Ural Branch of the Russian Academy of Sciences (Perm) studied the effect of trophoblastic β1-glycoprotein in the blood of pregnant women on pro-inflammatory immune cells.

10 Feb 2021

Scientists decipher the molecular blueprint for important receptor

In order for a drug to be effective at the right places in the body, it helps if scientists can predict as accurately as possible how the molecules of that drug will interact with human cells.

10 Feb 2021

Study identifies new therapeutic targets for treatment of obesity and type 2 diabetes

The GIP receptor in the central nervous system plays a crucial role in the regulation of body weight and food intake.

10 Feb 2021

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Researchers at the NYU Grossman School of Medicine have shown that a second dose of the Pfizer-BioNTech BNT162b2 vaccine may not offer any additional protection against coronavirus disease 2019 (COVID-19) over one dose among individuals previously infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Feb 2021

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Researchers at the Polish Academy of Sciences in Warsaw have identified a substrain of the recently emerged B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may confer resistance to antibody neutralization.

10 Feb 2021

Freiburg immunologists decipher anti-cancer drug's mode of operation

Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works.

10 Feb 2021

Could a SARS-CoV-2 accessory protein be responsible for certain COVID-19 symptoms?

Researchers highlight the potential causes of some COVID-19 symptoms. Early in the pandemic, the hallmark symptoms of COVID-19 include cough, fever, and shortness of breath. As the pandemic has evolved, more symptoms have emerged, such as loss of smell and taste, headache, intestinal issues, and abdominal pains.

10 Feb 2021

Modified lipids target the body’s endocannabinoid system to regulate pain and inflammation

When modified using a process known as epoxidation, two naturally occurring lipids are converted into potent agents that target multiple cannabinoid receptors in neurons, interrupting pathways that promote pain and inflammation, researchers report.

10 Feb 2021

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.

10 Feb 2021

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

Researchers at Northwestern University have noted high rates of asymptomatic and mild infection in a large community-based cohort and low levels of anti-SARS-CoV-2 immunoglobulin G antibody (IgG) in the general population of previously exposed people.

10 Feb 2021

Orally administered experimental drug halts SARS-CoV-2 replication, prevents infection

Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental drug EIDD-2801 halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue.

10 Feb 2021

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

Researchers in the United States and Canada have conducted a study showing that just a single dose of either the Pfizer-BioNTech or Moderna vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is likely to protect against emerging variants.

9 Feb 2021

Receptor News and Research

Study describes mechanism that limits immunosupressive activity of tumor-associated macrophages

Scientists demonstrate how glue points and sequence alignment information can flag residue SARS-CoV-2 variants

Study shows that SRC-3 also regulates human immune T regulatory cells

Researchers identify a pathway used by filoviruses to enter cells

Brain pericytes serve as a potential hub for SARS-CoV-2 infection

Higher proportion of male children develop COVID-19-related Multisystem Inflammatory Syndrome, finds study

New gut microbiome-based approach may have translational potential for cancer immunotherapy

New strategy to optimize the efficacy of neuropeptides for therapeutic applications

Study could help develop drugs for pregnancy maintenance, treat autoimmune diseases

Scientists decipher the molecular blueprint for important receptor

Study identifies new therapeutic targets for treatment of obesity and type 2 diabetes

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Freiburg immunologists decipher anti-cancer drug's mode of operation

Could a SARS-CoV-2 accessory protein be responsible for certain COVID-19 symptoms?

Modified lipids target the body’s endocannabinoid system to regulate pain and inflammation

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

Orally administered experimental drug halts SARS-CoV-2 replication, prevents infection

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News